Product Code: RP-ID-10294102 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10294102
Market Overview:
Fondaparinux Market, By Types (Branded and Generic), By End Use (Clinics, Hospitals, Ambulatory Surgical Centres, Diagnostic Centres and Home Care Settings), By Geography (North America, Europe, Asia Pacific, and Rest of the World) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025
REPORT HIGHLIGHTS
The fondaparinux market was valued at USD 388.9 million by 2017, growing with 6.4% CAGR during the forecast period, 2018-2025
Market Dynamics
Fondaparinux is a molecule that is widely used in the pharmaceutical industry. This particular molecule is used as an anticoagulant (prevents the development of blood clots) in the healthcare industry. This drug due to its molecular structure as compared to regular heparin shows more efficacy. It is majorly used in medical conditions such as knee or hip replacement, deep vein thrombosis (DVT) and Pulmonary Embolism (PE). Arixtra, a type of Fondaparinux is the U.S. FDA approved drug to treat cases of pulmonary embolism especially in cases of DVT surgeries.
The benefits it offers over heparin is one of the reasons why this particular therapeutic has grown in this specific industry. One of the significant factors that will drive the market growth is the increase in the number of cases in knee and hip replacement. Since OECD Health Statistics 2017, stated that on an average the cases of hip replacement increased 30% from the year 2000 to 2015. Anticoagulants are also provided to geriatric populations due to a number of complications that could arise due to age-related diseases.
On contrary, there is a significant amount of uncertainty when it comes to government regulations regarding the use of fondaparinux, pull back the industry growth. Furthermore, this product is not very commonly promoted by doctors due to its associated side effects such as breathing issues, allergic reactions, numbness and muscle weakness.
Types Takeaway
The two major segments for this are generic and branded. Fondaparinux has a generic form of it available as an injectable blood thinner, popularly known as Arixtra. One of the most common End Uses for this product is the treatment for DVT and pulmonary thromboembolism. This product is quite highly priced, one of the major reasons for it is due to an extremely difficult manufacturing process the drug has to go through. It is a highly stringent and complex process. This is also a reason why fondaparinux is consumed with limitations.
To a great extent, an improvement in the R&D facilities can drastically change the way these products are manufactured. Governments across the globe are promoting the practice of using generic drugs from a regulatory standpoint. Countries such as France, Japan, and Spain have all adopted policies that promote the use of these generic drugs as there is better control over the pricing for these as compared to branded products. From an end use perspective generally the drug is used in hospitals, clinics, ambulances, home care set ups and diagnostic facilities across the healthcare set up.
Regional Takeaway
An increase in the number of increased diseases, tumors, cardiovascular diseases in North Americas one of the reasons why North America is one of the leading users of the drug Fondaparinux. Illnesses such as haematological, neurological and CVD are increasingly predominant in North America. China is the second highest when it comes to consuming this product because the country is an evolving market from a pharmaceutical industry standpoint. It has been central when it comes to the manufacturing of various API’s from a global standpoint.
Key Vendor Takeaway
The key market players of this industry are GlaxoSmithKline Plc, Alchemia Ltd., Abbott Laboratories, Inc., Dr. Reddy’s Laboratories, Apotex, Inc., ScinoPharm Taiwan Ltd., Aurobindo Pharma and Lupin Pharmaceuticals. This is the consolidated industry, where handful companies capture significant revenue share.
Key players are engaged in new product introduction and merger and acquisitions to attract large customer base. For instance, in December 2017, Aurobindo Pharma received approval of Fondaparinux Sodium injection (5 mg/0.4 mL, 2.5 mg/0.5 mL, 10 mg/0.8 mL and 7.5 mg/0.6 mL single-dose prefilled syringes) from the US Food & Drug Administration (USFDA).
The market size and forecast for each segment and sub-segments has been considered as below:
Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE
Traders, Distributors, and Suppliers
Manufacturers
Government and Regional Agencies
Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY TYPE
Branded
Generic
MARKET, BY END USE
Ambulatory Surgical Centers
Diagnostic Centers
Home Care Settings
Clinics
Hospitals
MARKET, BY REGION
North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America
Related Reports
Proof of Quality & Reliability
